INmune Bio, Inc

(NASDAQ:INMB)

Latest On INmune Bio, Inc (INMB):

Date/Time Type Description Signal Details
2023-05-08 11:51 ESTNewsINmune Bio gets FDA IND approval for prostate cancer immunotherapyN/A
2023-05-04 00:56 ESTNewsINmune Bio GAAP EPS of -$0.36N/A
2023-05-04 00:55 ESTNewsINmune Bio, Inc. (INMB) Q1 2023 Earnings Call TranscriptN/A
2023-04-24 07:21 ESTNewsINmune Bio: Alzheimer's Disease Treatment Lottery TicketN/A
2023-04-03 22:50 ESTNewsINmune rises 7% after company files application to begin trial of cancer treatmentN/A
2023-03-03 08:05 ESTNewsINmune Bio, Inc. (INMB) Q4 2022 Earnings Call TranscriptN/A
2023-03-02 17:57 ESTNewsINmune Bio GAAP EPS of -$1.52 beats by $0.14, revenue of $0.37M beats by $0.17MN/A
2023-03-02 03:13 ESTNewsINmune Bio FY 2022 Earnings PreviewN/A
2023-02-08 22:42 ESTNewsINmune Bio to fund Alzheimer’s trial with over $6M R&D rebatesN/A
2023-01-05 10:19 ESTNewsINmune Bio: INKmune For Solid Tumors And Other Potential CatalystsN/A
2022-11-22 21:57 ESTNewsINmune Bio, High Risk, Higher RewardN/A
2022-11-22 03:40 ESTNewsINmune Bio, High Risk, Higher Reward.N/A
2022-11-14 10:27 ESTNewsINmune receives green signal from Canada to begin trial of XPro1595 in mild Alzheimer’s DiseaseN/A
2022-11-04 04:11 ESTNewsINmune Bio, Inc. (INMB) Q3 2022 Earnings Call TranscriptN/A
2022-11-02 18:55 ESTNewsINmune Bio GAAP EPS of -$0.43N/A
2022-11-02 03:01 ESTNewsINmune Bio Q3 2022 Earnings PreviewN/A
2022-08-03 22:07 ESTNewsINmune Bio GAAP EPS of -$0.38N/A
2022-08-03 22:07 ESTNewsINmune Bio, Inc's (INMB) CEO RJ Tesi on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-03 07:18 ESTNewsINmune Bio Q2 2022 Earnings PreviewN/A
2022-06-22 21:25 ESTNewsINmune Bio gets US patent covering use of XPro for neurological disordersN/A
2022-05-25 18:53 ESTNewsINmune Bio: Possibly The Once In A Lifetime DipN/A
2022-05-24 20:43 ESTNewsINmune Bio down 22% on Alzheimer's candidate mid-stage trial holdN/A
2022-05-23 22:31 ESTNewsINmune says FDA put on hold application to start phase 2 trial of Alzheimer's treatmentN/A
2022-05-08 17:53 ESTNewsINmune Bio's (INMB) CEO RJ Tesi on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-06 04:08 ESTNewsINmune Bio GAAP EPS of -$0.39, revenue of $0.2MN/A
2022-05-05 04:57 ESTNewsINmune Bio Q1 2022 Earnings PreviewN/A
2022-04-13 18:54 ESTNewsINmune starts dosing in phase 2 XPro1595 trial to treat neuroinflammation due to Alzheimer’sN/A
2022-04-05 10:20 ESTNewsINmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid TumorsN/A
2022-03-04 06:45 ESTNewsINmune Bio GAAP EPS of -$1.88 misses by $1.30, revenue of $0.18MN/A
2022-03-04 06:44 ESTNewsINmune Bio, Inc. (INMB) CEO Raymond J. Tesi on Q4 2021 Results - Earnings Call TranscriptN/A
2022-01-17 15:18 ESTNewsINmune Bio, The Biotech In My Stable For After Cassava SciencesN/A
2021-12-03 15:54 ESTNewsWarning: INMB is at high risk of performing badlyN/A
2021-11-04 11:05 ESTNewsINmune Bio, Inc. (INMB) CEO R. J. Tesi on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-02 17:58 ESTNewsINmune Bio Q3 2021 Earnings PreviewN/A
2021-10-13 23:24 ESTNewsINmune Bio A No-Brainer InvestmentN/A
2021-09-09 06:27 ESTNewsINmune slides 20% following 192.5K share offering from XencorN/A
2021-09-02 21:16 ESTNewsINmune Bio jumps 11% after XPro data in Alzheimer’s diseaseN/A
2021-08-18 11:30 ESTNewsINmune Bio: High-Risk High-Reward Alzheimer's PlayN/A
2021-08-12 19:07 ESTNewsOur Bullish Take On INmune Bio's Drug PipelineN/A
2021-08-08 14:03 ESTNewsINmune Bio, Inc. (INMB) CEO David Moss on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-05 06:48 ESTNewsINmune Bio EPS misses by $0.10N/A
2021-07-26 17:55 ESTNewsINMune releases design for phase 2 trial of Alzheimer's candidate XPro1595N/A
2021-07-23 01:31 ESTNewsINmune Bio acquires LUMICKS' z-Movi Cell Avidity AnalyzerN/A
2021-07-21 12:41 ESTNewsINmune enters $15M credit facility to fund purchase of Xencor optionN/A
2021-07-21 12:27 ESTNewsCassava, Annovis, and INmune PTs raised at Maxim on aducanumab approvalN/A
2021-07-21 12:26 ESTNewsINmune Bio surges ahead of key data readoutN/A
2021-07-21 12:25 ESTNewsINmune treats first patient in early-stage INKmune MDS studyN/A
2021-07-21 12:24 ESTNewsINmune Bio: Underfollowed AD Player With Very Bullish August MomentumN/A
2021-07-21 12:24 ESTNewsINmune Bio under pressure on launch of $40M direct offeringN/A
2021-05-06 14:04 ESTNewsINmune Bio, Inc. (INMB) CEO RJ Tesi on Q1 2021 Results - Earnings Call TranscriptN/A

About INmune Bio, Inc (INMB):

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in La Jolla, California.

INMB Quotes by TradingView

See Advanced Chart

General

  • Name INmune Bio, Inc
  • Symbol INMB
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 5
  • Fiscal Year EndDecember
  • IPO Date2019-02-04
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.inmunebio.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 15957.57
  • Price/Book (Most Recent Quarter) 5.6
  • Enterprise Value Revenue 17878.76
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.05
  • Next Year EPS Estimate -$1.87
  • Next Quarter EPS Estimate -$0.38
  • Operating Margin -112016%
  • Return on Assets -23%
  • Return on Equity -39%
  • Revenue 10916
  • Earnings Per Share -$0.62
  • Revenue Per Share $0
  • Gross Profit 10916
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 222.05 million
  • PE Ratio -3.47
  • Analyst Target Price $29.67
  • Book Value Per Share $2.88
View More

Share Statistics

  • Shares Outstanding 14.93 million
  • Shares Float 8.87 million
  • % Held by Insiders 4507%
  • % Held by Institutions 12.61%
  • Shares Short 364561
  • Shares Short Prior Month 447423
  • Short Ratio 1.11
  • Short % of Float 4%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • Beta 2.96
  • 52 Week High $29.99
  • 52 Week Low $2.22
  • 50 Day Moving Average 17.86
  • 200 Day Moving Average 13.14
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

INmune Bio, Inc (INMB) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

INmune Bio, Inc (INMB) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-04$10916-$0.26-$0.3115.45%
2020-09-302020-11-05$N/A-$0.36-$0.17-108.7%
2020-06-302020-08-05$N/A-$0.20-$0.2313.04%
2020-03-312020-05-14$N/A-$0.19-$0.219.52%
2019-12-312020-03-11$N/A-$0.22-$0.247.37%
2019-09-302019-11-08$N/A-$0.28-$0.19-44.85%
2019-06-302019-08-09$N/A-$0.04-$0.2080%
2019-03-312019-05-15$N/A-$0.20-$0.19-5.26%
2018-12-312019-03-29$N/A-$0.21-$0.19-10.53%

INmune Bio, Inc (INMB) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

INmune Bio, Inc (INMB) Chart:

INmune Bio, Inc (INMB) News:

Below you will find a list of latest news for INmune Bio, Inc (INMB) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

INmune Bio, Inc (INMB) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-06-202.55.2CALL0 16241.86TRUE00
2025-06-2052.8CALL0 184177.53TRUE00
2025-06-207.51.77CALL175 587169.84TRUE-0.07-0.04
2025-06-20101.1CALL439 2177185.32FALSE00
2025-06-2012.50.68CALL55 753189.88FALSE0.150.28
2025-06-20150.45CALL7 607195.26FALSE0.10.29
2025-06-2017.50.25CALL0 82286.44FALSE00
2025-06-20200.2CALL15 628198.85FALSE0.20
2025-06-202.50.21PUT31 414309.4FALSE-0.06-0.22
2025-06-2050.61PUT23 295221.3FALSE0.610
2025-06-207.51.5PUT7 461183.03FALSE1.50
2025-06-20103.44PUT12 531210.02TRUE3.440
2025-06-2012.50PUT0 0242.81TRUE00
2025-06-20158.05PUT0 0241.06TRUE00
2025-06-2017.50PUT0 0199.35TRUE00
2025-06-20200PUT0 0253.82TRUE00
2025-07-182.56CALL4 0340.75TRUE60
2025-07-1850CALL0 0250.86TRUE00
2025-07-187.50CALL0 0375.25TRUE00
2025-07-18103CALL3 0287.08FALSE30
2025-07-1812.52CALL1 0245.4FALSE20
2025-07-18150CALL0 0385.02FALSE00
2025-07-182.50PUT0 0303.85FALSE00
2025-07-1852.09PUT1 0350.22FALSE2.090
2025-07-187.53.62PUT1 0326.56FALSE3.620
2025-07-18105.35PUT2 0310.23TRUE5.350
2025-07-1812.50PUT0 0283.38TRUE00
2025-07-18150PUT0 0254.24TRUE00
2025-09-192.55.6CALL0 38161.16TRUE00
2025-09-1955.03CALL3 745249.82TRUE5.030
2025-09-197.54.11CALL21 773234.68TRUE0.50.14
2025-09-19103.3CALL11 4255219.18FALSE0.350.12
2025-09-1912.53.1CALL2 1375233.48FALSE3.10
2025-09-19152.55CALL171 1234222.1FALSE2.550
2025-09-1917.51.95CALL0 455187.12FALSE00
2025-09-19201.63CALL10 2136200.18FALSE-0.07-0.04
2025-09-192.50.85PUT10 728280.85FALSE0.040.05
2025-09-1952.11PUT0 704261.46FALSE00
2025-09-197.53.7PUT0 246238.06FALSE00
2025-09-19105.4PUT0 704233.63TRUE00
2025-09-1912.57.46PUT0 206211.26TRUE00
2025-09-19159.6PUT0 7199.3TRUE00
2025-09-1917.510.7PUT0 0205.25TRUE00
2025-09-192013.27PUT0 8185.6TRUE00
2025-12-192.56CALL0 8192.73TRUE00
2025-12-1955.8CALL2 6249.04TRUE5.80
2025-12-197.53.8CALL0 19160.95TRUE00
2025-12-19103.4CALL32 31170.4FALSE3.40
2025-12-1912.52.8CALL0 12181.17FALSE00
2025-12-19152.2CALL0 34152.48FALSE00
2025-12-192.50.9PUT0 11164.89FALSE00
2025-12-1952.15PUT5 94195.5FALSE2.150
2025-12-197.53.7PUT18 40183.57FALSE3.70
2025-12-19100PUT0 0166.61TRUE00
2025-12-1912.50PUT0 0164.05TRUE00
2025-12-19150PUT0 0155.4TRUE00

Latest INMB Trades:

Date Shares Price
Jun 13, 2022 7:46 PM EST120$6.635
Jun 13, 2022 7:50 PM EST100$6.62
Jun 13, 2022 7:51 PM EST60$6.605
Jun 13, 2022 7:55 PM EST365$6.62
Jun 13, 2022 7:56 PM EST10$6.62

INmune Bio, Inc (INMB) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020014985/0001213900-20-014985-index.htm
2019-06-27UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1711754/000000000019010444/0000000000-19-010444-index.htm
2019-07-24UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1711754/000000000019011485/0000000000-19-011485-index.htm
2020-03-31UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1711754/000000000020002785/0000000000-20-002785-index.htm
2020-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000110465920008253/0001104659-20-008253-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1711754/000110465920021049/0001104659-20-021049-index.htm
2019-02-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000120919119008770/0001209191-19-008770-index.htm
2019-02-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000120919119008772/0001209191-19-008772-index.htm
2019-08-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000121390019015380/0001213900-19-015380-index.htm
2019-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390019015549/0001213900-19-015549-index.htm
2019-08-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390019016070/0001213900-19-016070-index.htm
2019-08-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000121390019016187/0001213900-19-016187-index.htm
2019-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000121390019016453/0001213900-19-016453-index.htm
2019-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000121390019016455/0001213900-19-016455-index.htm
2019-08-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000121390019016514/0001213900-19-016514-index.htm
2019-08-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390019016813/0001213900-19-016813-index.htm
2019-09-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390019017204/0001213900-19-017204-index.htm
2019-09-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390019017510/0001213900-19-017510-index.htm
2019-09-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390019017870/0001213900-19-017870-index.htm
2019-09-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390019017874/0001213900-19-017874-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000121390019017904/0001213900-19-017904-index.htm
2019-09-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390019018359/0001213900-19-018359-index.htm
2019-09-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390019018683/0001213900-19-018683-index.htm
2019-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390019019236/0001213900-19-019236-index.htm
2019-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390019019987/0001213900-19-019987-index.htm
2019-10-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390019020655/0001213900-19-020655-index.htm
2019-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1711754/000121390019022556/0001213900-19-022556-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390019022948/0001213900-19-022948-index.htm
2019-11-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390019024216/0001213900-19-024216-index.htm
2019-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000121390019024949/0001213900-19-024949-index.htm
2019-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000121390019024951/0001213900-19-024951-index.htm
2019-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000121390019024954/0001213900-19-024954-index.htm
2019-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000121390019024956/0001213900-19-024956-index.htm
2019-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000121390019024961/0001213900-19-024961-index.htm
2019-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000121390019024968/0001213900-19-024968-index.htm
2019-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000121390019024971/0001213900-19-024971-index.htm
2019-11-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390019025038/0001213900-19-025038-index.htm
2019-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390019025204/0001213900-19-025204-index.htm
2019-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390019026351/0001213900-19-026351-index.htm
2020-01-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020000044/0001213900-20-000044-index.htm
2020-01-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000121390020000646/0001213900-20-000646-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020000847/0001213900-20-000847-index.htm
2020-01-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020001935/0001213900-20-001935-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020003050/0001213900-20-003050-index.htm
2020-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1711754/000121390020003972/0001213900-20-003972-index.htm
2020-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1711754/000121390020003973/0001213900-20-003973-index.htm
2020-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1711754/000121390020003974/0001213900-20-003974-index.htm
2020-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020005391/0001213900-20-005391-index.htm
2020-03-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020005786/0001213900-20-005786-index.htm
2020-03-1110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1711754/000121390020005916/0001213900-20-005916-index.htm
2020-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020006109/0001213900-20-006109-index.htm
2020-03-24S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1711754/000121390020007264/0001213900-20-007264-index.htm
2020-03-31CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1711754/000121390020008226/0001213900-20-008226-index.htm
2020-04-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020008917/0001213900-20-008917-index.htm
2020-04-14POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1711754/000121390020009194/0001213900-20-009194-index.htm
2020-04-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020009372/0001213900-20-009372-index.htm
2020-04-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1711754/000121390020009374/0001213900-20-009374-index.htm
2020-04-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020009642/0001213900-20-009642-index.htm
2020-04-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020009707/0001213900-20-009707-index.htm
2020-04-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020009822/0001213900-20-009822-index.htm
2020-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020009925/0001213900-20-009925-index.htm
2020-04-24424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1711754/000121390020010039/0001213900-20-010039-index.htm
2020-04-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020010301/0001213900-20-010301-index.htm
2020-05-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020010962/0001213900-20-010962-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020011278/0001213900-20-011278-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020011855/0001213900-20-011855-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1711754/000121390020012056/0001213900-20-012056-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020012422/0001213900-20-012422-index.htm
2020-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020012725/0001213900-20-012725-index.htm
2020-05-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020013101/0001213900-20-013101-index.htm
2020-06-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020014985/0001213900-20-014985-index.htm
2020-07-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020017207/0001213900-20-017207-index.htm
2020-07-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020017343/0001213900-20-017343-index.htm
2020-07-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1711754/000121390020017565/0001213900-20-017565-index.htm
2020-07-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020017615/0001213900-20-017615-index.htm
2020-07-16424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1711754/000121390020017634/0001213900-20-017634-index.htm
2020-07-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020017924/0001213900-20-017924-index.htm
2020-07-218-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020018013/0001213900-20-018013-index.htm
2020-07-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020018871/0001213900-20-018871-index.htm
2020-07-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020019177/0001213900-20-019177-index.htm
2020-08-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020019888/0001213900-20-019888-index.htm
2020-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1711754/000121390020020373/0001213900-20-020373-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020020662/0001213900-20-020662-index.htm
2020-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020020897/0001213900-20-020897-index.htm
2020-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020022288/0001213900-20-022288-index.htm
2020-08-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020022769/0001213900-20-022769-index.htm
2020-08-19424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1711754/000121390020022773/0001213900-20-022773-index.htm
2020-08-21DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1711754/000121390020023303/0001213900-20-023303-index.htm
2020-09-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020025123/0001213900-20-025123-index.htm
2020-09-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020025397/0001213900-20-025397-index.htm
2020-09-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020026558/0001213900-20-026558-index.htm
2020-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020027055/0001213900-20-027055-index.htm
2020-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020028229/0001213900-20-028229-index.htm
2020-09-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020028780/0001213900-20-028780-index.htm
2020-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020029548/0001213900-20-029548-index.htm
2020-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020030205/0001213900-20-030205-index.htm
2020-10-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020033364/0001213900-20-033364-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1711754/000121390020035280/0001213900-20-035280-index.htm
2020-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000121390020035449/0001213900-20-035449-index.htm
2019-02-11SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000218/0001640334-19-000218-index.htm
2019-02-11SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000219/0001640334-19-000219-index.htm
2019-02-11SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000220/0001640334-19-000220-index.htm
2019-02-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000238/0001640334-19-000238-index.htm
2019-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000337/0001640334-19-000337-index.htm
2019-03-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000350/0001640334-19-000350-index.htm
2019-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000374/0001640334-19-000374-index.htm
2019-03-2910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1711754/000164033419000466/0001640334-19-000466-index.htm
2019-04-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000543/0001640334-19-000543-index.htm
2019-04-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000577/0001640334-19-000577-index.htm
2019-04-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000661/0001640334-19-000661-index.htm
2019-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000708/0001640334-19-000708-index.htm
2019-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000755/0001640334-19-000755-index.htm
2019-05-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000758/0001640334-19-000758-index.htm
2019-05-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000761/0001640334-19-000761-index.htm
2019-05-094/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000793/0001640334-19-000793-index.htm
2019-05-10DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000800/0001640334-19-000800-index.htm
2019-05-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000817/0001640334-19-000817-index.htm
2019-05-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000820/0001640334-19-000820-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000834/0001640334-19-000834-index.htm
2019-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1711754/000164033419000853/0001640334-19-000853-index.htm
2019-05-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000899/0001640334-19-000899-index.htm
2019-05-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000911/0001640334-19-000911-index.htm
2019-05-204/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000940/0001640334-19-000940-index.htm
2019-05-204/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000942/0001640334-19-000942-index.htm
2019-05-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000971/0001640334-19-000971-index.htm
2019-05-248-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000974/0001640334-19-000974-index.htm
2019-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419000996/0001640334-19-000996-index.htm
2019-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001033/0001640334-19-001033-index.htm
2019-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001035/0001640334-19-001035-index.htm
2019-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001039/0001640334-19-001039-index.htm
2019-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001049/0001640334-19-001049-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001052/0001640334-19-001052-index.htm
2019-06-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001070/0001640334-19-001070-index.htm
2019-06-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001099/0001640334-19-001099-index.htm
2019-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001161/0001640334-19-001161-index.htm
2019-06-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001172/0001640334-19-001172-index.htm
2019-06-21S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1711754/000164033419001189/0001640334-19-001189-index.htm
2019-06-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001220/0001640334-19-001220-index.htm
2019-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001240/0001640334-19-001240-index.htm
2019-06-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001254/0001640334-19-001254-index.htm
2019-06-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001259/0001640334-19-001259-index.htm
2019-07-03424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1711754/000164033419001285/0001640334-19-001285-index.htm
2019-07-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001293/0001640334-19-001293-index.htm
2019-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001309/0001640334-19-001309-index.htm
2019-07-18S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1711754/000164033419001410/0001640334-19-001410-index.htm
2019-07-24CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001451/0001640334-19-001451-index.htm
2019-07-26424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1711754/000164033419001474/0001640334-19-001474-index.htm
2019-07-29PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001480/0001640334-19-001480-index.htm
2019-07-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001494/0001640334-19-001494-index.htm
2019-08-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001511/0001640334-19-001511-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001540/0001640334-19-001540-index.htm
2019-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1711754/000164033419001563/0001640334-19-001563-index.htm
2019-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001566/0001640334-19-001566-index.htm
2019-08-09DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1711754/000164033419001577/0001640334-19-001577-index.htm
2019-07-02EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1711754/999999999519001521/9999999995-19-001521-index.htm
2019-07-26EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1711754/999999999519001719/9999999995-19-001719-index.htm
2020-04-02EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1711754/999999999520000673/9999999995-20-000673-index.htm
2020-04-20EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1711754/999999999520000788/9999999995-20-000788-index.htm

INmune Bio, Inc (INMB) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of INmune Bio, Inc (INMB). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 4507%
Institutional Ownership: 1261%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-05-08-06:00Linda F Powers10% Share HolderBuy61,667.009.00555,003.001,120,000.00https://www.sec.gov/Archives/edgar/data/1711754/000164033419000820/0001640334-19-000820-index.htm
2019-06-03-06:00Linda F Powers10% Share HolderBuy10,000.006.0060,000.001,130,000.00https://www.sec.gov/Archives/edgar/data/1711754/000164033419001052/0001640334-19-001052-index.htm
2019-05-06-06:00David J MossCFO, Treasurer & SecretaryBuy5,000.009.0045,000.001,210,417.00https://www.sec.gov/Archives/edgar/data/1711754/000164033419000761/0001640334-19-000761-index.htm
2019-06-03-06:00David J MossCFO, Treasurer & SecretaryBuy10,000.006.0060,000.001,220,417.00https://www.sec.gov/Archives/edgar/data/1711754/000164033419001035/0001640334-19-001035-index.htm
2019-08-20David J MossCFO, Treasurer & SecretaryBuy77.005.65435.051,220,494.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019016455/0001213900-19-016455-index.htm
2019-08-20David J MossCFO, Treasurer & SecretaryBuy239.005.651,350.351,220,733.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019016455/0001213900-19-016455-index.htm
2019-08-20David J MossCFO, Treasurer & SecretaryBuy2,000.005.6511,300.001,222,733.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019016455/0001213900-19-016455-index.htm
2019-08-20David J MossCFO, Treasurer & SecretaryBuy72.005.65406.801,222,805.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019016455/0001213900-19-016455-index.htm
2019-08-20David J MossCFO, Treasurer & SecretaryBuy236.005.651,333.401,223,041.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019016455/0001213900-19-016455-index.htm
2019-08-20David J MossCFO, Treasurer & SecretaryBuy376.005.652,124.401,223,417.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019016455/0001213900-19-016455-index.htm
2019-09-11Mark William LowdellChief Scientific OfficerBuy2,918.006.2318,178.561,506,251.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019017904/0001213900-19-017904-index.htm
2019-05-02-06:00Raymond Joseph TesiChairmanBuy11,100.009.90109,890.001,526,933.00https://www.sec.gov/Archives/edgar/data/1711754/000164033419000758/0001640334-19-000758-index.htm
2019-06-03-06:00Raymond Joseph TesiPresident & CEOBuy10,000.006.0060,000.001,536,933.00https://www.sec.gov/Archives/edgar/data/1711754/000164033419001033/0001640334-19-001033-index.htm
2019-08-09Raymond Joseph TesiPresident & CEOBuy100.007.20720.001,537,033.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019015380/0001213900-19-015380-index.htm
2019-08-09Raymond Joseph TesiPresident & CEOBuy900.007.146,428.791,537,933.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019015380/0001213900-19-015380-index.htm
2019-08-09Raymond Joseph TesiPresident & CEOBuy1,000.006.916,909.501,538,933.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019015380/0001213900-19-015380-index.htm
2019-08-20Raymond Joseph TesiPresident & CEOBuy100.005.96596.001,539,033.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019016453/0001213900-19-016453-index.htm
2019-08-20Raymond Joseph TesiPresident & CEOBuy100.005.96596.001,539,133.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019016453/0001213900-19-016453-index.htm
2019-08-20Raymond Joseph TesiPresident & CEOBuy100.005.96596.001,539,233.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019016453/0001213900-19-016453-index.htm
2019-08-20Raymond Joseph TesiPresident & CEOBuy100.005.96596.001,539,333.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019016453/0001213900-19-016453-index.htm
2019-08-20Raymond Joseph TesiPresident & CEOBuy100.005.96596.001,539,433.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019016453/0001213900-19-016453-index.htm
2019-08-20Raymond Joseph TesiPresident & CEOBuy100.005.96596.001,539,533.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019016453/0001213900-19-016453-index.htm
2019-08-20Raymond Joseph TesiPresident & CEOBuy100.005.96596.001,539,633.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019016453/0001213900-19-016453-index.htm
2019-08-20Raymond Joseph TesiPresident & CEOBuy100.005.96596.001,539,733.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019016453/0001213900-19-016453-index.htm
2019-08-20Raymond Joseph TesiPresident & CEOBuy100.005.96596.001,539,833.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019016453/0001213900-19-016453-index.htm
2019-08-20Raymond Joseph TesiPresident & CEOBuy100.005.92592.391,539,933.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019016453/0001213900-19-016453-index.htm
2019-08-20Raymond Joseph TesiPresident & CEOBuy1,000.006.036,030.801,540,933.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019016453/0001213900-19-016453-index.htm
2020-01-27Linda F Powers10% Share HolderSell220,000.004.601,012,000.00210,000.00https://www.sec.gov/Archives/edgar/data/1711754/000110465920008253/0001104659-20-008253-index.htm
2019-06-03-06:00Scott JudaDirectorBuy10,000.006.0060,000.0022,500.00https://www.sec.gov/Archives/edgar/data/1711754/000164033419001039/0001640334-19-001039-index.htm
2019-08-20Scott JudaDirectorBuy2,500.006.0015,000.0025,000.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019016514/0001213900-19-016514-index.htm
2019-08-21Scott JudaDirectorBuy2,500.006.0015,000.0027,500.00https://www.sec.gov/Archives/edgar/data/1711754/000121390019016514/0001213900-19-016514-index.htm